NASDAQ: CBRSCerebras Systems Inc Stock
$204.86-16.41 (-7.42%)
Updated Jul 2, 2026
Shares of semiconductor and chip... find out Why CBRS Price Moved with a free WallStreetZen account
Why Price MovedCBRS Price
$204.86
Fair Value Price
N/A
Market Cap
$46.41B
52 Week Low
$160.81
52 Week High
$386.34
P/E
N/A
P/B
-238.38x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-11.28
Operating Cash Flow
N/A
Beta
1.6
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CBRS Overview
Cerebras Systems Inc. is a leading innovator in artificial intelligence infrastructure. The company develops and manufactures an advanced AI compute platform, integrating proprietary hardware systems and software. This platform is delivered in rack-mountable units, suitable for deployment in data centers, scaling all the way up to supercomputer-level capabilities. At its core is the groundbreaking Wafer-Scale Engine (WSE), a unique chip that encompasses an entire silicon wafer. This innovation is specifically engineered to deliver superior performance and speed compared to conventional GPUs, addressing the intensive computational demands of inference, Generative AI, and a broad spectrum of other AI applications. Cerebras serves a diverse clientele, including leading hyperscalers, advanced foundation model laboratories, AI-native and digital-first businesses, large enterprises, and key players in Sovereign AI initiatives. With operations spanning the United States, Europe, the Middle East, Africa, and other international markets, Cerebras maintains a significant global footprint. The company was established in 2015 and is headquartered in Sunnyvale, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CBRS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Semiconductor
Industry Rating
B
CBRS
Ranked#61 of 67
Ranked#61 of 67
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $975.56 | A | |
| $360.45 | A | |
| $136.53 | B |
Be the first to know about important CBRS news, forecast changes, insider trades & much more!
CBRS News
Overview
Due Diligence Score
–
Industry Average (36)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CBRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CBRS's short-term assets ($3.58B) exceed its short-term liabilities ($1.43B)
Short-term Liabilities Financials
CBRS's short-term assets ($3.58B) exceed its long-term liabilities ($768.44M)
Long-term Liabilities Financials
CBRS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more CBRS due diligence checks available for Premium users.
Valuation
CBRS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-238.38x
Industry
13.55x
CBRS's financial health
Profit margin
Revenue
$193.4M
Net Income
-$14.0M
Profit Margin
-7.2%
Assets to liabilities
Assets
$4.9B
Liabilities
$2.2B
Debt to equity
-11.28
CBRS's short-term assets ($3.58B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBRS's short-term assets ($3.58B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBRS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CBRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.3M
Investing
-$236.6M
Financing
$2.0B
CBRS vs Semiconductor Stocks
Cerebras Systems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.